retatrutide availability 2025 Lilly Prepares for FDA Filing Following Additional Phase 3 Data in Diabetes, CVD When Will Retatrutide Be Available?

Never discontinue therapy without medical guidance, as abrupt cessation can affect glycemic control in diabetes patients

According to the World Health Organization, a person is considered obese if their body mass index (BMI) is 30 kg/m 2 or greater

Welcome to the most effective body recomposition tool currently available.

High Expenditure and Supply Chain Issues: Major Limitations In the global GLP-1 receptor agonist market, arising challenges are the high expenses of these drugs, which pose a hurdle for many patients

[18] [19] A referral to a registered dietitian is strongly advisable if nutritional intake is a concern, consistent with NICE guidance on obesity management (CG189)

The emergence of biosimilars and cost-effective manufacturing methods may reduce financial obstacles, but need regulatory frameworks that promote competitive markets while upholding quality standards